<DOC>
	<DOCNO>NCT00536471</DOCNO>
	<brief_summary>Study F1J-US-HMFS comprise two identical multicenter , 9-month , randomize , placebo-controlled , double-blind , trial ( HMFSa HMFSb ) . The purpose study compare efficacy safety Duloxetine 60 milligram ( mg ) daily placebo depression patient age 18-65 . Data two trial report individual pooled analysis . Pooling two study allow increased power detect difference duloxetine placebo secondary exploratory objective . Only one data lock plan study , patient complete study procedure .</brief_summary>
	<brief_title>A Study Comparing Duloxetine Placebo Assessing Energy Vitality Major Depressive Disorder ( MDD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Male female outpatient Aged 1865 meet Diagnostic Statistical Manual Mental Disorders Fourth Edition , Text Revision ( DSMIVTR ) diagnostic criterion Major Depressive Disorder ( MDD ) Have MontgomeryAsberg Depression Rating Scale ( MADRS ) total score least 22 visit 1 2 Have Clinical Global Impressions Severity Scale ( CGIS ) score least 4 visit 1 2 Have degree understand patient provide inform consent , complete protocol require assessment communicate intelligibly investigator study coordinator . Patients judge clinically serious suicidal risk opinion investigator Patients prior history bipolar disorder , psychosis , schizophrenia Patients current ( within past six month ) DSMIVTR primary Axis I disorder MDD Patients uncontrolled narrowangle glaucoma Patients serious medical illness opinion investigator stabilize likely require intervention , hospitalization , use exclude medication course study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>